IRF2 Biomarker Analysis for Immunotherapy Response Prediction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Cancer cells evade immune detection by downregulating interferon regulatory factor 2 (IRF2), leading to reduced MHC-I expression and increased PD-L1 expression, which impairs immune recognition and checkpoint blockade therapy effectiveness.

Innovation Solution

Measuring IRF2 levels in tumors to identify patients who would benefit from checkpoint blockade therapy and restoring IRF2 expression using interferons or interferon inducers, either alone or in conjunction with checkpoint inhibitors, to enhance immunotherapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If cancer cells downregulate IRF2 expression, then immune evasion is enhanced through reduced MHC-I and increased PD-L1, but checkpoint blockade therapy effectiveness deteriorates

Engineering Contradiction:

Improveimmune evasion capabilityVSAvoidcheckpoint blockade therapy effectiveness

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent measures IRF2 expression levels before initiating checkpoint blockade therapy to identify patients who are likely to respond. This preliminary assessment prevents wasting therapy on patients whose tumors have low IRF2 expression and are therefore unlikely to benefit, thereby improving the overall reliability and effectiveness of the treatment approach.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses interferon inducers to alter the expression parameters of IRF2, MHC-I, and PD-L1 in tumors with low IRF2 expression. By changing these molecular parameters through pharmacological intervention, the tumor becomes more responsive to checkpoint blockade therapy, resolving the contradiction between immune evasion and therapy effectiveness.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If IRF2 expression is restored in tumors, then MHC-I expression increases and PD-L1 expression decreases, but treatment complexity increases due to combination therapy requirements

Engineering Contradiction:

Improveimmunotherapy effectivenessVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs interferon inducers as intermediary agents that mediate the restoration of IRF2 expression and the subsequent modulation of MHC-I and PD-L1 levels. This intermediary approach simplifies the overall treatment strategy by using a single class of compounds (interferon inducers) to achieve multiple therapeutic effects, rather than requiring complex combination therapies with multiple different mechanisms of action.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20220299513A1IRF2 as a prognostic biomarker and target for augmenting immunotherapy

Publication Date: 2022.09.22 UNIV OF MASSACHUSETTS

AI summary

Methods of identifying and treating subjects with immune checkpoint inhibitors and interferon inducers.